USA 1o (69.4%) & 2o (30.6%) 1yr Mean 0.61 (SD 0.32) (n=1705) Wu 2011 Valdez 2005 USA 1o (75%) & 2o (25%) popn NR Mean 0.96 (SD 0.23) (n=819) 1o primary; 2o secondary; % percentage; AMI acute myocardial infarction; CAD coronary artery disease; CHD coronary heart disease; combo combination; CV cardiovascular; CVD cardiovascular disease; IHD ischemic heart disease; LLT lipid lowering therapy; MI myocardial infarction; mth month; n total number of patients; NR not reported; PDC proportion of days covered; popn population; SD standard deviation; USA United States of America; yr year eTable 5: Summary of persistence with lipid lowering therapy dichotomous outcomes (n=22) – Study ID Time Country CVD Outcome Definition Persistence (%) n point history Primary prevention in the general population (i.e. population not selected on basis of previous events of CVD risk) Europe MI (7.0%); 3 yrs Dichotomous - number Persistent patients continued 84% (n=161646) Svensson 2015 (Denmark) unstable (%) of patients in a statin treatment angina persistence category (2.0%); HF (3.0%); angina/IHD (10.0%) Latry 2011 Europe No history 15 mths Dichotomous - number Percentage of patients still treated 44.3% (n=3560) (France) (%) of patients in a at the end of the period persistence category N. America NR 12 mths Dichotomous - number Percentage of a group given a 35% (n= 140) Husser 2005 Any Statin: (USA) (%) of patients in a specific therapy that continues on 36% (n=80) Atorvastatin: persistence category that treatment 100% (n=3) Fluvastatin:
Wu 2011 USA 1o (69.4%) & 2o (30.6%) 1yr Mean 0.61 (SD 0.32) (n=1705) Valdez 2005 USA 1o (75%) & 2o (25%) popn NR Mean 0.96 (SD 0.23) (n=819) 1o primary; 2o secondary; % percentage; AMI acute myocardial infarction; CAD coronary artery disease; CHD coronary heart disease; combo combination; CV cardiovascular; CVD cardiovascular disease; IHD ischemic heart disease; LLT lipid lowering therapy; MI myocardial infarction; mth month; n total number of patients; NR not reported; PDC proportion of days covered; popn population; SD standard deviation; USA United States of America; yr year eTable 5: Summary of persistence with lipid lowering therapy – dichotomous outcomes (n=22) Study ID Time point Country CVD history Outcome Definition Persistence (%) n Primary prevention in the general population (i.e. population not selected on basis of previous events of CVD risk) Svensson 2015 Europe (Denmark) MI (7.0%); unstable angina (2.0%); HF (3.0%); angina/IHD (10.0%) 3 yrs Dichotomous - number (%) of patients in a persistence category Persistent patients continued statin treatment 84% (n=161646) Latry 2011 Europe (France) No history 15 mths Dichotomous - number (%) of patients in a persistence category Percentage of patients still treated at the end of the period 44.3% (n=3560) Husser 2005 N. America (USA) NR 12 mths Dichotomous - number (%) of patients in a persistence category Percentage of a group given a specific therapy that continues on that treatment Any Statin: 35% (n= 140) Atorvastatin: 36% (n=80) Fluvastatin: 100% (n=3)
icmo_a_1281109_sm0750.docx